Generation and Characterization of Anti-Filovirus Nucleoprotein Monoclonal Antibodies
AbstractFiloviruses cause lethal hemorrhagic fever in humans. The filovirus nucleoprotein (NP) is expressed in high abundance in infected cells and is essential for virus replication. To generate anti-filovirus monoclonal antibodies (mAbs) against the NP, mice were immunized with peptides known as B-cell epitopes corresponding to different filovirus NPs, and hybridomas were screened using FLAG-tagged filovirus NP constructs. Numerous mAbs were identified, isotyped, and characterized. The anti-NP mAbs demonstrated different ranges of binding affinities to various filovirus NPs. Most of the clones specifically detected both recombinant and wild-type NPs from different filoviruses, including Ebola (EBOV), Sudan (SUDV), Bundibugyo (BDBV), Marburg (MARV), Tai Forest (TAFV), and Reston (RESTV) viruses in western blot analysis. The mAbs were also able to detect native NPs within the cytoplasm of infected cells by immunofluorescence confocal microscopy. Thus, this panel of mAbs represents an important set of tools that may be potentially useful for diagnosing filovirus infection, characterizing virus replication, and detecting NP–host protein interactions. View Full-Text
Share & Cite This Article
Rahim, M.N.; Wang, M.; Wang, T.; He, S.; Griffin, B.D.; Kobasa, D.; Yang, R.; Du, Z.; Qiu, X. Generation and Characterization of Anti-Filovirus Nucleoprotein Monoclonal Antibodies. Viruses 2019, 11, 259.
Rahim MN, Wang M, Wang T, He S, Griffin BD, Kobasa D, Yang R, Du Z, Qiu X. Generation and Characterization of Anti-Filovirus Nucleoprotein Monoclonal Antibodies. Viruses. 2019; 11(3):259.Chicago/Turabian Style
Rahim, Md N.; Wang, Min; Wang, Tong; He, Shihua; Griffin, Bryan D.; Kobasa, Darwyn; Yang, Ruifu; Du, Zongmin; Qiu, Xiangguo. 2019. "Generation and Characterization of Anti-Filovirus Nucleoprotein Monoclonal Antibodies." Viruses 11, no. 3: 259.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.